Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells $198,000.00 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $18.00, for a total transaction of $198,000.00. Following the completion of the transaction, the insider directly owned 416,775 shares of the company’s stock, valued at $7,501,950. The trade was a 2.57% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Wednesday, March 11th, Susan Bobulsky sold 41,338 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.17, for a total transaction of $544,421.46.

Adaptive Biotechnologies Stock Performance

ADPT opened at $17.07 on Thursday. Adaptive Biotechnologies Corporation has a fifty-two week low of $9.90 and a fifty-two week high of $20.76. The company has a fifty day moving average of $14.41 and a two-hundred day moving average of $15.67. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of -51.73 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The company had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. During the same quarter in the previous year, the company earned ($0.20) earnings per share. The firm’s revenue for the quarter was up 35.1% on a year-over-year basis. On average, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently bought and sold shares of the company. Perceptive Advisors LLC purchased a new position in Adaptive Biotechnologies during the first quarter worth about $2,117,000. Bank of America Corp DE raised its stake in Adaptive Biotechnologies by 52.3% during the first quarter. Bank of America Corp DE now owns 1,227,917 shares of the company’s stock worth $17,043,000 after purchasing an additional 421,645 shares during the period. Amundi purchased a new position in Adaptive Biotechnologies during the first quarter worth about $148,000. California State Teachers Retirement System raised its stake in Adaptive Biotechnologies by 28.4% during the first quarter. California State Teachers Retirement System now owns 143,658 shares of the company’s stock worth $1,994,000 after purchasing an additional 31,782 shares during the period. Finally, SummitTX Capital L.P. purchased a new position in Adaptive Biotechnologies during the first quarter worth about $4,409,000. 99.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on ADPT. Guggenheim reiterated a “buy” rating and issued a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. JPMorgan Chase & Co. lowered their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. Finally, Morgan Stanley lowered their price target on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.57.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.